On February 25, 2026, PrecisionLife and Ovation.io announced Phase 1 results of their collaboration, identifying over 2,500 genetic signatures mapping to 1,100 genes and 15 main mechanisms driving GLP-1 receptor agonist (GLP-1 RA) efficacy12.
Analysis of 4,600 patients' data enabled prediction of strong and weak responders based on BMI and HbA1c changes, with biomarkers identified in 100% of patients, linked to type-II diabetes, cardiovascular disease, and lipid metabolism12.
The partnership, initiated in December 2025, is expanding to Phase 2 with up to 25,000 patients to validate efficacy, identify safety/tolerability markers, and stratify subgroups12.
These biomarkers support drug development, clinical trial enrichment, patient stratification, and potential payor-facing tests for reimbursement12.
CEOs Steve Gardner (PrecisionLife) and Curt Medeiros (Ovation.io) highlighted the potential for precision medicine to improve outcomes and reduce waste in GLP-1 therapies12.
Sources:
1. https://www.bioindustry.org/resource/precisionlife-and-ovation-identify-first-potential-genetic-biomarkers-to-quantitatively-predict-glp-1-efficacy-response.html
2. https://precisionlife.com/news-and-events/precisionlife-and-ovation-identify-first-genetic-biomarkers-to-predict-glp-1-efficacy-response